Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Standard Biotools (LAB) over the last 14 years, with Q3 2025 value amounting to $33.9 million.

  • Standard Biotools' Gains from Investment Securities rose 8424920.95% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.9 million, marking a year-over-year increase of 8424920.95%. This contributed to the annual value of $39.2 million for FY2024, which is 32191.74% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Gains from Investment Securities is $33.9 million, which was up 8424920.95% from $35.4 million recorded in Q2 2025.
  • Standard Biotools' 5-year Gains from Investment Securities high stood at $37.6 million for Q1 2025, and its period low was $40228.0 during Q3 2024.
  • Over the past 5 years, Standard Biotools' median Gains from Investment Securities value was $661000.0 (recorded in 2022), while the average stood at $6.8 million.
  • As far as peak fluctuations go, Standard Biotools' Gains from Investment Securities crashed by 9956.51% in 2024, and later soared by 8424920.95% in 2025.
  • Over the past 5 years, Standard Biotools' Gains from Investment Securities (Quarter) stood at $598000.0 in 2021, then increased by 10.54% to $661000.0 in 2022, then dropped by 24.36% to $500000.0 in 2023, then grew by 6.6% to $533000.0 in 2024, then surged by 6266.23% to $33.9 million in 2025.
  • Its last three reported values are $33.9 million in Q3 2025, $35.4 million for Q2 2025, and $37.6 million during Q1 2025.